评估动机性访谈与短信干预优化乳腺癌内分泌治疗依从性的随机III期试验(Alliance A191901):GETSET方案
GETSET是一项正在进行的四臂随机临床试验,针对激素受体阳性乳腺癌幸存者,比较短信提醒、动机性访谈、两者联合与增强常规护理对内分泌治疗依从性、患者报告结局及资源利用的影响。计划招募1180名参与者,按1:1:1:1随机分组,并按年龄和种族分层,年轻女性和黑人女性各占30%。主要分析比较12个月时各研究组经Pillsy测量的内分泌治疗依从性。
要点
- GETSET试验测试短信提醒和/或动机性访谈能否改善激素受体阳性乳腺癌患者的内分泌治疗依从性。
- 计划招募1180名参与者,四臂1:1:1:1随机,按年龄和种族分层,年轻及黑人女性各占30%。
- 主要分析为12个月时经Pillsy药瓶盖监测系统测量的内分泌治疗依从性组间比较。
核心结论
- 该试验旨在测试短信提醒和/或动机性访谈对改善激素受体阳性乳腺癌幸存者内分泌治疗依从性、患者报告结局及资源利用需求的疗效和效果。
研究设计与样本
- Alliance A191901是一项正在进行的四臂随机临床试验,分为短信提醒组、动机性访谈组、短信提醒联合动机性访谈组和增强常规护理组。
- 参与者按1:1:1:1比例随机分配到四组,随机化按年龄和种族分层,并过度抽样年轻女性和黑人女性,每组占研究人群的30%。
- 假设失访率约11%,计划招募1180名参与者。
- 随机分配到干预组的参与者积极参与干预9个月,所有参与者通过Pillsy药瓶盖药物事件监测系统和Alliance ePRO调查应用程序(即Patient Cloud)随访依从性数据和患者报告结局终点。
- 主要分析比较12个月时各研究组经Pillsy测量的内分泌治疗依从性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormone receptor-positive (HR +) breast cancer is the most common type of breast cancer in the USA but has excellent long-term outcomes in recent decades, in part due to effective oral endocrine therapy (ET). ET medications are typically prescribed for 5 to 10 years, depending on the risk of recurrence, and must be taken daily. One limiting factor to ET efficacy is nonadherence, with high-risk groups for nonadherence including younger women and Black women. METHODS: The Alliance for Clinical Trials in Oncology (Alliance) trial A191901 is an ongoing, four-arm (text message reminder (TMR), motivational interviewing (MI), TMR plus MI, or enhanced usual care) randomized clinical trial that tests the efficacy and effect of two interventions (TMR and/or MI) on improved ET adherence, patient-reported outcomes (PROs), and resource use requirements among HR + breast cancer survivors. Participants are randomized in a 1:1:1:1 ratio to the four arms. With an assumed loss to follow-up of approximately 11%, we plan to recruit 1180 participants. Randomization is stratified based on age and race to ensure balance between the arms, and we oversample younger and Black women, with each group representing 30% of the study population. Participants randomized to an intervention will actively participate in the intervention for 9 months, and all participants will be followed for adherence data and PRO endpoints, through the use of the Pillsy cap medication event monitoring system and Alliance ePRO survey app (i.e., Patient Cloud). The primary analysis will compare Pillsy-measured ET adherence among study arms at 12 months. DISCUSSION: This multisite study will not only define strategies to improve adherence to breast cancer oral therapies, but it will also potentially support strategies in large cooperative research groups that can increase delivery and tolerability of ET, involve diverse patient populations in clinical research, and engage patients effectively in interventional studies, using remote and cost-effective delivery methods. TRIAL REGISTRATION: Clinicaltrials.gov NCT04379570 . Registered on 7 May 2020.
引用
- Ivory J, Wheeler SB, Drier S, et al. Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol. Trials. 2023. PMID: 37828596. doi:10.1186/s13063-023-07672-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。